Filing Details

Accession Number:
0001209191-22-004795
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-25 16:36:02
Reporting Period:
2022-01-21
Accepted Time:
2022-01-25 16:36:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1396814 Pacira Biosciences Inc. PCRX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1296965 Marie Kristen Williams C/O Pacira Biosciences, Inc.
5401 West Kennedy Boulevard, Suite 890
Tampa FL 33609
Chief Administrative Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-21 200 $38.35 22,468 No 4 M Direct
Common Stock Disposition 2022-01-21 200 $65.41 22,268 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-01-21 200 $0.00 200 $38.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,766 2028-06-13 No 4 M Direct
Footnotes
  1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.365 to $65.460, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.